Four times yearly, we collect data from US retina specialists on a range of practice of medicine and practice management issues. We began this survey process in 2008. The data we collect are analyzed and presented in our US Retina Quarterly Updates.
We measure and analyze key metrics of the US retinal market four times per year, including:
• Use of Eylea, Lucentis, Avastin, Macugen, Visudyne PDT, and Jetrea;
• IVT injections;
• DME treatments;
• Corticosteroid use;
• Photocoagulation volume and photocoagulators used;
• Vitrectomy volume and location;
• Reusable and disposable instruments.
• We also provide a full-year forecast for US retinal procedures (including IVT injections) and a comparison with volumes during the prior year.
Our updates include trend analysis based on comparisons with information gathered in previous years. All information is presented in color charts and tables with concise narratives for enhanced clarity and context.
Our analysis for Q3-2018 includes 51 US retinal surveys with data from 85 retina specialists. Consequently, these results do not provide the precision required for exact measures of market share. Market Scope sources additional information from our proprietary disease models, database of retina specialists, primary research, and public data sources. In some cases, this additional information is used to extrapolate survey data to total market estimates.
All Market Scope reports are continuously updated, and we appreciate your feedback at any time. If you have any questions or suggestions for improvements, please contact us.
4 licensing types are available for this subscription:
SINGLE USER LICENSE
A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.